{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.358","value":"1.16"},{"groupId":"OG001","spread":"8.629","value":"-0.43"}]}],"title":"Week 1, n=244, 490"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.510","value":"1.89"},{"groupId":"OG001","spread":"9.644","value":"0.78"}]}],"title":"Week 2, n=242, 490"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.464","value":"2.47"},{"groupId":"OG001","spread":"9.739","value":"1.50"}]}],"title":"Week 4, n=227, 483"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.158","value":"3.23"},{"groupId":"OG001","spread":"8.708","value":"1.19"}]}],"title":"Week 6, n=205, 470"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.751","value":"2.91"},{"groupId":"OG001","spread":"9.227","value":"1.78"}]}],"title":"Week 8, n=190, 472"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.188","value":"4.28"},{"groupId":"OG001","spread":"9.539","value":"2.02"}]}],"title":"Week 12, n=174, 450"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.975","value":"5.87"},{"groupId":"OG001","spread":"10.419","value":"2.38"}]}],"title":"Week 16, n=143, 403"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.688","value":"5.73"},{"groupId":"OG001","spread":"9.530","value":"2.10"}]}],"title":"Week 20, n=132, 371"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.912","value":"3.77"},{"groupId":"OG001","spread":"9.399","value":"2.03"}]}],"title":"Week 24, n=99, 262"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.038","value":"2.72"},{"groupId":"OG001","spread":"10.328","value":"1.64"}]}],"title":"Week 28, n=74, 211"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.281","value":"4.28"},{"groupId":"OG001","spread":"9.676","value":"1.62"}]}],"title":"Week 32, n=67, 196"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.109","value":"5.42"},{"groupId":"OG001","spread":"10.205","value":"2.11"}]}],"title":"Week 36, n=62, 186"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.919","value":"4.83"},{"groupId":"OG001","spread":"9.895","value":"0.78"}]}],"title":"Week 40, n=59, 171"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.005","value":"5.53"},{"groupId":"OG001","spread":"8.846","value":"1.16"}]}],"title":"Week 44, n=59, 165"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.606","value":"4.01"},{"groupId":"OG001","spread":"11.134","value":"2.89"}]}],"title":"End of Treatment, n=237, 467"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.432","value":"4.27"},{"groupId":"OG001","spread":"10.113","value":"2.11"}]}],"title":"4-week FU, n=220, 422"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.707","value":"1.73"},{"groupId":"OG001","spread":"9.955","value":"0.74"}]}],"title":"12-week FU, n=206, 429"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.803","value":"0.14"},{"groupId":"OG001","spread":"9.176","value":"-1.90"}]}],"title":"24-week FU, n=202, 395"}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"490"}],"units":"Participants"}],"description":"Heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=100 Gi/L) in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"MEAN","populationDescription":"Safety DB Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)","title":"Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase","type":"SECONDARY","unitOfMeasure":"beats per minute"}